Literature DB >> 19330167

Pandemic preparedness: toward a universal influenza vaccine.

Kenny Roose1, Walter Fiers, Xavier Saelens.   

Abstract

The possible emergence of a new influenza pandemic is considered a major threat for human health worldwide. Pandemics start by the introduction or reintroduction and spread in the human population of an influenza virus subtype against which almost nobody has protective immunity. Currently used influenza vaccines provide good protection only against antigenically matching influenza strains. However, neither the timing nor the subtype of the next pandemic virus is known. Therefore, different approaches are being pursued in anticipation of this pandemic threat. In the present article, we review approaches that aim to induce heterosubtypic immunity, that is, protection against challenge with influenza A viruses belonging to two or more subtypes. Experimental and epidemiological studies indicate that natural infection can provide some heterosubtypic immunity, possibly involving cellular immune responses directed against matrix and/or nucleoprotein as well as humoral responses against neuraminidase. Other approaches have focused on the use of conserved epitopes of the viral proteins, including matrix protein 2 ectodomain (M2e) and nucleoprotein (NP). Proof-of-concept of protection by these novel vaccines has been obtained in animal models, and promising results from several clinical trials have recently been reported. Demonstrating the efficacy of these new vaccines against a potential pandemic influenza endowed with human transmissibility remains a major challenge. Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19330167     DOI: 10.1358/dnp.2009.22.2.1334451

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  20 in total

Review 1.  Coverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model system.

Authors:  Jason Botten; John Sidney; Bianca R Mothé; Bjoern Peters; Alessandro Sette; Maya F Kotturi
Journal:  Microbiol Mol Biol Rev       Date:  2010-06       Impact factor: 11.056

Review 2.  Development of universal influenza vaccines based on influenza virus M and NP genes.

Authors:  M Zheng; J Luo; Z Chen
Journal:  Infection       Date:  2013-11-01       Impact factor: 3.553

3.  A dual purpose universal influenza vaccine candidate confers protective immunity against anthrax.

Authors:  Maria T Arévalo; Junwei Li; Diana Diaz-Arévalo; Yanping Chen; Ashley Navarro; Lihong Wu; Yongyong Yan; Mingtao Zeng
Journal:  Immunology       Date:  2016-12-05       Impact factor: 7.397

4.  Intranasal immunization with influenza antigens conjugated with cholera toxin subunit B stimulates broad spectrum immunity against influenza viruses.

Authors:  Junwei Li; Maria T Arévalo; Yanping Chen; Olivia Posadas; Jacob A Smith; Mingtao Zeng
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

5.  Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine.

Authors:  Gary J Nabel; Anthony S Fauci
Journal:  Nat Med       Date:  2010-12       Impact factor: 53.440

6.  Significant impact of sequence variations in the nucleoprotein on CD8 T cell-mediated cross-protection against influenza A virus infections.

Authors:  Weimin Zhong; Feng Liu; Libo Dong; Xiuhua Lu; Kathy Hancock; Ellis L Reinherz; Jacqueline M Katz; Suryaprakash Sambhara
Journal:  PLoS One       Date:  2010-05-11       Impact factor: 3.240

7.  Universal vaccines: shifting to one for many.

Authors:  Antonio Cassone; Rino Rappuoli
Journal:  MBio       Date:  2010-05-18       Impact factor: 7.867

Review 8.  Development of a universal CTL-based vaccine for influenza.

Authors:  Diego Esteban Cargnelutti; María Victoria Sánchez; Nora Marta Mattion; Eduardo Alberto Scodeller
Journal:  Bioengineered       Date:  2013-01-21       Impact factor: 3.269

9.  Generation of New M2e-HA2 Fusion Chimeric Peptide to Development of a Recombinant Fusion Protein Vaccine.

Authors:  Ali Ameghi; Behzad Baradaran; Khosrow Aghaiypour; Abolfazl Barzegar; Yones Pilehvar-Soltanahmadi; Masood Moghadampour; Morteza Taghizadeh; Nosratollah Zarghami
Journal:  Adv Pharm Bull       Date:  2015-12-31

10.  A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease.

Authors:  Maya F Kotturi; Jason Botten; John Sidney; Huynh-Hoa Bui; Lori Giancola; Matt Maybeno; Josie Babin; Carla Oseroff; Valerie Pasquetto; Jason A Greenbaum; Bjoern Peters; Joey Ting; Danh Do; Lo Vang; Jeff Alexander; Howard Grey; Michael J Buchmeier; Alessandro Sette
Journal:  PLoS Pathog       Date:  2009-12-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.